{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:32:11Z","timestamp":1787963531121,"version":"build-2784847793"},"reference-count":49,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100016266","name":"Magyar T\u00fcd\u0151gy\u00f3gy\u00e1sz T\u00e1rsas\u00e1g","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23AR075872"],"award-info":[{"award-number":["K23AR075872"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K23AR077073-01A1"],"award-info":[{"award-number":["K23AR077073-01A1"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jid.2022.04.020","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T05:27:23Z","timestamp":1653024443000},"page":"2896-2908.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0899-4671","authenticated-orcid":false,"given":"Thomas K.","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9313-7895","authenticated-orcid":false,"given":"Isabelle","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9684-0335","authenticated-orcid":false,"given":"Rebecca","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7192-7936","authenticated-orcid":false,"given":"Matthew T.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8393-8915","authenticated-orcid":false,"given":"Junwen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1422-772X","authenticated-orcid":false,"given":"Varsha","family":"Parthasarathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8833-6080","authenticated-orcid":false,"given":"Zachary A.","family":"Bordeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-1284","authenticated-orcid":false,"given":"Martin Prince","family":"Alphonse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6547-8852","authenticated-orcid":false,"given":"Madan M.","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4281-8882","authenticated-orcid":false,"given":"Vivek","family":"Naranbhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7980-4620","authenticated-orcid":false,"given":"Alexander","family":"Gusev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3356-692X","authenticated-orcid":false,"given":"Jihad","family":"Alhariri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8264-834X","authenticated-orcid":false,"given":"Nicole R.","family":"LeBoeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7793-654X","authenticated-orcid":false,"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2795-7059","authenticated-orcid":false,"given":"Laura C.","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-8686","authenticated-orcid":false,"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2443-8395","authenticated-orcid":false,"given":"Julie R.","family":"Brahmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7841-9392","authenticated-orcid":false,"given":"Sewon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7387-3094","authenticated-orcid":false,"given":"Yevgeniy R.","family":"Semenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3736-1515","authenticated-orcid":false,"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2022.04.020_bib1","doi-asserted-by":"crossref","first-page":"e001622","DOI":"10.1136\/jitc-2020-001622","article-title":"Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade \u22652 immune-related adverse events in patients with cancer [published correction appears in J Immunother Cancer 2021;9:1]","volume":"8","author":"Allouchery","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jid.2022.04.020_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40264-019-00875-6","article-title":"Occurrences and outcomes of immune checkpoint inhibitors-induced vitiligo in cancer patients: A retrospective cohort study","volume":"43","author":"Babai","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.jid.2022.04.020_bib3","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s40618-020-01226-4","article-title":"Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study","volume":"43","author":"Bai","year":"2020","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.jid.2022.04.020_bib4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000253915","article-title":"Malignant melanoma and vitiligo","volume":"139","author":"Balabanov","year":"1969","journal-title":"Dermatologica"},{"key":"10.1016\/j.jid.2022.04.020_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A\u00a0Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jid.2022.04.020_bib6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: an overview","volume":"75","author":"Bihan","year":"2020","journal-title":"Therapies. Therapie"},{"key":"10.1016\/j.jid.2022.04.020_bib7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jid.2022.04.020_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/17425255.2016.1120287","article-title":"New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors","volume":"12","author":"Ciccarese","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"393","key":"10.1016\/j.jid.2022.04.020_bib9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study [published correction appears in Lancet 2019;393:132]","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2022.04.020_bib10","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management","volume":"80","author":"Coleman","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2022.04.020_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.jid.2022.04.020_bib12","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jid.2022.04.020_bib13","doi-asserted-by":"crossref","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","article-title":"Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies","volume":"93","author":"Dubey","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jid.2022.04.020_bib14","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2022.04.020_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug\u00a0reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jid.2022.04.020_bib16","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.3390\/ijms20225731","article-title":"Melanoma and vitiligo: in good company","volume":"20","author":"Failla","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2022.04.020_bib17","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2022.04.020_bib18","doi-asserted-by":"crossref","first-page":"e000604","DOI":"10.1136\/jitc-2020-000604","article-title":"Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy","volume":"8","author":"Haanen","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jid.2022.04.020_bib19","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [publidhed correction appears in Am Oncol 2018;29:iv264\u20126]","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jid.2022.04.020_bib20","doi-asserted-by":"crossref","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jid.2022.04.020_bib21","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2022.04.020_bib22","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.04.020_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2022.04.020_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Db","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jid.2022.04.020_bib25","doi-asserted-by":"crossref","unstructured":"Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy [published correction appears in Front Pharmacol 2017;8:311]. Front Pharmacol 2017;8:49.","DOI":"10.3389\/fphar.2017.00049"},{"key":"10.1016\/j.jid.2022.04.020_bib26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label Phase III trial","volume":"36","author":"Larkin","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2022.04.020_bib27","first-page":"1","article-title":"Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses","author":"Le","year":"2021","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jid.2022.04.020_bib28","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2165\/00002018-200427120-00003","article-title":"Data quality management in pharmacovigilance","volume":"27","author":"Lindquist","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.jid.2022.04.020_bib29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"the WHO Global ICSR Database System: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf J"},{"key":"10.1016\/j.jid.2022.04.020_bib30","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jid.2022.04.020_bib31","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1111\/ijd.14811","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review","volume":"59","author":"Maloney","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jid.2022.04.020_bib32","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jaad.2020.03.029","article-title":"Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: a multicenter case series","volume":"83","author":"Molina","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2022.04.020_bib33","doi-asserted-by":"crossref","unstructured":"Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, et\u00a0al. Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy [published correction appears in J Clin Oncol 2017;35:2590]. J Clin Oncol 2017;35:709\u201317.","DOI":"10.1200\/JCO.2016.68.2005"},{"key":"10.1016\/j.jid.2022.04.020_bib34","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance","volume":"15","author":"Raschi","year":"2020","journal-title":"Target Oncol"},{"key":"10.1016\/j.jid.2022.04.020_bib35","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jid.2022.04.020_bib36","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2022.04.020_bib37","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"issue":"39","key":"10.1016\/j.jid.2022.04.020_bib38","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update [published correction appears in J Clin Oncol 2022;40:315]","author":"Schneider","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2022.04.020_bib39","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jid.2022.04.020_bib40","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jid.2022.04.020_bib41","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti\u2013PD-1 and anti\u2013PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2022.04.020_bib42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of\u00a0cutaneous immune-related adverse events with increased survival in\u00a0treated patients with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2022.04.020_bib43","doi-asserted-by":"crossref","first-page":"102596","DOI":"10.1016\/j.autrev.2020.102596","article-title":"Risk of scleroderma according to the type of immune checkpoint inhibitors","volume":"19","author":"Terrier","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jid.2022.04.020_bib44","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III\u2013IV melanoma\u00a0receiving immunotherapy and its association with survival:\u00a0A systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2022.04.020_bib45","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3740","article-title":"Bullous pemphigoid associated with anti-programmed cell death Protein 1 and anti-programmed cell death ligand 1 therapy: a review of the literature","volume":"101","author":"Tsiogka","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2022.04.020_bib47","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40264-019-00899-y","article-title":"Investigating overlap in signals from EVDAS, FAERS, and VigiBase\u00ae","volume":"43","author":"Vogel","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.jid.2022.04.020_bib48","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2021.03.094","article-title":"Epidemiology and risk factors for the development of cutaneous toxicities\u00a0in patients treated with immune-checkpoint inhibitors: a United\u00a0States population-level analysis","volume":"86","author":"Wongvibulsin","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2022.04.020_bib49","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/CMR.0000000000000500","article-title":"Anti-programmed cell death-1 therapy-associated bullous disorders: a systematic review of the literature","volume":"28","author":"Zhao","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jid.2022.04.020_bib50","doi-asserted-by":"crossref","first-page":"730320","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: A systemic review and meta-analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X2200389X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X2200389X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:27:36Z","timestamp":1758302856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X2200389X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0022202X2200389X"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2022.04.020","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2022.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}